Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 09, 2018 08:30 ET | Source: Verona Pharma plc

Verona Pharma to Present Clinical Trial Data of RPL554 for COPD Maintenance Treatment at American Thoracic Society 2018 International Conference

LONDON, May 09, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
May 08, 2018 02:00 ET | Source: Verona Pharma plc

Verona Pharma plc Operational Update and Financial Results for the First Quarter Ended March 31, 2018

Announced positive top-line data from two Phase 2 clinical trials ahead of schedule Met primary and key secondary endpoints in 403 patient Phase 2b clinical trial for maintenance treatment of COPD ...
May 04, 2018 08:30 ET | Source: Verona Pharma plc

Verona Pharma to Present at Bio€quity Europe 2018

LONDON, May 04, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
May 02, 2018 08:30 ET | Source: Verona Pharma plc

Verona Pharma to Announce Operational Update and Financial Results for First Quarter Ended March 31, 2018

LONDON, May 02, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
April 11, 2018 02:00 ET | Source: Verona Pharma plc

Verona Pharma Announces Departure of Chief Medical Officer

LONDON, April 11, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or “the Company”), a clinical-stage biopharmaceutical company focused on developing and...
March 26, 2018 02:00 ET | Source: Verona Pharma plc

Verona Pharma Reports Positive Top-Line Data from Phase 2b Clinical Trial of RPL554 for Maintenance Treatment of COPD

Primary endpoint met; RPL554 produced clinically and statistically significant improvements in lung function at all dose levels Clinically relevant secondary endpoints were also met, including...
March 15, 2018 08:00 ET | Source: Verona Pharma plc

Verona Pharma to Present at Upcoming Healthcare Investor Conferences

LONDON, March 15, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
March 02, 2018 02:00 ET | Source: Verona Pharma plc

Verona Pharma Reports Positive Top-Line Data from Phase 2a Trial with RPL554 in Cystic Fibrosis Patients

LONDON, March 02, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
February 27, 2018 02:00 ET | Source: Verona Pharma plc

Verona Pharma plc ("Verona Pharma" or the "Company") Reports Operational Update and Financial Results for Full Year Ended December 31, 2017

LONDON, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
February 22, 2018 08:45 ET | Source: Verona Pharma plc

Verona Pharma to Announce Operational Update and Financial Results for Full Year ended December 31, 2017

LONDON, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...